ライフサイエンスコーパス: germ cell tumour

1 transcriptional programme similar to that of germ cell tumours.

2 chemotherapy-induced apoptosis in testicular germ cell tumours.

3 elatively frequent loss of heterozygosity in germ cell tumours.

4 miology, genetics, and biology of testicular germ cell tumours.

5 s in the clinical management of intracranial germ-cell tumours.

6 cal management of patients with intracranial germ-cell tumours.

7 progression-free survival for patients with germ-cell tumours.

8 maeric embryos, and is associated with human germ-cell tumours.

9 cryptorchidism, risk factors for testicular germ-cell tumours.

10 34 patients with cancer, 53% had testicular germ-cell tumours.

11 eview the assessment and management of early germ-cell tumours.

12 e of approaches offer high survival in early germ-cell tumours.

13 tility and increases risk for development of germ-cell tumours.

14 5% CI 20.9-27.5]) and lowest in survivors of germ cell tumours (14.0 [11.5-16.6]).

15 ise the consensus on how to treat testicular germ cell tumours and focus on a few controversies and i

16 Differentiated tissues within ovarian germ cell tumours and in testicular teratomas lacked det

17 ntly overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the blad

18 ion or death in patients with poor prognosis germ-cell tumours and an unfavourable tumour marker decl

19 Testicular germ cell tumours are at the crossroads of developmental

20 In contrast, advanced testicular germ cell tumours are cured in over 80% of patients usin

21 Testicular germ cell tumours are highly sensitive to radiotherapy a

22 Testicular germ cell tumours are hypersentive to chemotherapy and c

23 Ovarian germ cell tumours are rare, but curable at all stages of

24 Germ-cell tumours are a heterogeneous group of neoplasms

25 Up to 80% of metastatic germ-cell tumours are curable with conventional chemothe

26 Patients with germ-cell tumours are managed by a diverse array of spec

27 Poor prognosis germ-cell tumours are only cured in about half of patien

28 the results obtained in treating metastatic germ-cell tumours are superior to those with other solid

29 operitoneal, or mediastinal non-seminomatous germ cell tumours based on histological findings or clin

30 Management of paediatric extracranial germ-cell tumours carries a unique set of challenges.

31 expressed ectopically in the 833K testicular germ cell tumour cell line.

32 Paediatric germ-cell tumours differ from the adolescent and adult d

33 a indicating fewer second primary testicular germ-cell tumours favour carboplatin use, these findings

34 opting practices developed for managing male germ cell tumours (GCTs).

35 Germ-cell tumours (GCTs) are derived from germ cells and

36 stratification, and treatment approaches for germ-cell tumours have evolved disparately along several

37 Intracranial germ cell tumours (IGCTs) are a group of rare heterogene

38 cells (PGCs), as well as the suppression of germ cell tumours in mice.

39 The management of intracranial germ-cell tumours is complex because of varied clinical

40 of in certain pathological contexts such as germ-cell tumours, melanoma or human immunodeficiency vi

41 Fewer than 70 new cases of malignant ovarian germ cell tumours (MOGCTs) are seen each year in the UK.

42 rs, the malignant cells in 73% of testicular germ-cell tumours (seminomas and teratomas), expressed h

43 Tumours within this group are testicular germ-cell tumours (such as benign teratoma, epidermoid c

44 icipants of the 2013 Third International CNS Germ Cell Tumour Symposium (Cambridge, UK) agreed to und

45 Testicular germ cell tumour (TGCT) is the most common cancer in you

46 A sizable fraction of testicular germ cell tumour (TGCT) risk is expected to be explained

47 identified multiple risk loci for testicular germ cell tumour (TGCT), revealing a polygenic model of

48 of the genetic susceptibility to testicular germ cell tumour (TGCT).

49 sease is a strong risk factor for testicular germ cell tumour (TGCT).

50 Testicular germ-cell tumours (TGCT) affect 1 in 500 men and are the

51 Testicular germ cell tumours (TGCTs) are histologically heterogeneo

52 Testicular germ cell tumours (TGCTs) are the most common cancer in

53 Testicular germ-cell tumours (TGCTs) represent the model of a curab

54 es that control susceptibility to testicular germ-cell tumours (TGCTs), the most common cancer affect

55 In the second mixed germ cell tumour, the NSTGCT component was methylated fo

56 Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstr

57 New, second primary testicular germ-cell tumours were reported in ten patients allocate

58 tements encompassing aspects of intracranial germ-cell tumour work-up, staging, treatment, and follow